Myasterix (CV-MG01) / CuraVac - LARVOL DELTA

Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - P1/2; N=24; Completed; Sponsor: CuraVac; Active, not recruiting ➔ Completed; Trial completion date: Nov 2019 ➔ Sep 2018; Trial primary completion date: Sep 2019 ➔ Sep 2018

Clinical • Trial completion • Trial completion date • Trial primary completion date